JP7170341B2 - 新規低分子化合物 - Google Patents

新規低分子化合物 Download PDF

Info

Publication number
JP7170341B2
JP7170341B2 JP2020515882A JP2020515882A JP7170341B2 JP 7170341 B2 JP7170341 B2 JP 7170341B2 JP 2020515882 A JP2020515882 A JP 2020515882A JP 2020515882 A JP2020515882 A JP 2020515882A JP 7170341 B2 JP7170341 B2 JP 7170341B2
Authority
JP
Japan
Prior art keywords
disease
cancer
pharmaceutical composition
cpt
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533399A (ja
JP2020533399A5 (enExample
Inventor
ビンウェイ ルー
Original Assignee
セレピュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレピュート インコーポレイテッド filed Critical セレピュート インコーポレイテッド
Publication of JP2020533399A publication Critical patent/JP2020533399A/ja
Publication of JP2020533399A5 publication Critical patent/JP2020533399A5/ja
Application granted granted Critical
Publication of JP7170341B2 publication Critical patent/JP7170341B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2020515882A 2017-09-13 2018-09-12 新規低分子化合物 Active JP7170341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (3)

Publication Number Publication Date
JP2020533399A JP2020533399A (ja) 2020-11-19
JP2020533399A5 JP2020533399A5 (enExample) 2021-10-21
JP7170341B2 true JP7170341B2 (ja) 2022-11-14

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515882A Active JP7170341B2 (ja) 2017-09-13 2018-09-12 新規低分子化合物

Country Status (9)

Country Link
US (3) US11186550B2 (enExample)
EP (1) EP3681874B1 (enExample)
JP (1) JP7170341B2 (enExample)
KR (1) KR102644045B1 (enExample)
CN (1) CN111372921B (enExample)
AU (1) AU2018331371C1 (enExample)
CA (1) CA3075649A1 (enExample)
IL (1) IL273242B2 (enExample)
WO (1) WO2019055528A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523383A (ja) * 2019-02-27 2022-04-22 セレピュート インコーポレイテッド キナゾリノン化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102644045B1 (ko) 2017-09-13 2024-03-05 셀리퓨트, 인코포레이티드 신규한 소분자 화합물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051974A2 (en) 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
JP2006501180A (ja) 2002-06-27 2006-01-12 ジ エンドウメント フォア リサーチ イン ヒューマン バイオロジー インコーポレイテッド Ａｌｄｈの阻害に有効な化合物
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
US20150164896A1 (en) 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
WO2017103615A1 (en) 2015-12-16 2017-06-22 Liverpool School Of Tropical Medicine Combination product

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759097B2 (en) 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
CN105008515A (zh) 2012-12-28 2015-10-28 小利兰·斯坦福大学托管委员会 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
KR102644045B1 (ko) 2017-09-13 2024-03-05 셀리퓨트, 인코포레이티드 신규한 소분자 화합물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501180A (ja) 2002-06-27 2006-01-12 ジ エンドウメント フォア リサーチ イン ヒューマン バイオロジー インコーポレイテッド Ａｌｄｈの阻害に有効な化合物
WO2005051974A2 (en) 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
US20150164896A1 (en) 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
WO2017103615A1 (en) 2015-12-16 2017-06-22 Liverpool School Of Tropical Medicine Combination product

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Qian, Wei; Salamoun, Joseph; Wang, Jingnan; Roginskaya, Vera; Van Houten, Bennett; Wipf, Peter，The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak，Bioorganic & Medicinal Chemistry Letters ，2015年，25(4),，856-863

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523383A (ja) * 2019-02-27 2022-04-22 セレピュート インコーポレイテッド キナゾリノン化合物
JP7597722B2 (ja) 2019-02-27 2024-12-10 セレピュート インコーポレイテッド キナゾリノン化合物
US12454514B2 (en) 2019-02-27 2025-10-28 Cerepeut, Inc. Quinazolinone compounds

Also Published As

Publication number Publication date
JP2020533399A (ja) 2020-11-19
US11186550B2 (en) 2021-11-30
US20200216400A1 (en) 2020-07-09
AU2018331371B2 (en) 2024-02-15
EP3681874A4 (en) 2021-01-13
CA3075649A1 (en) 2019-03-21
IL273242A (en) 2020-04-30
AU2018331371A1 (en) 2020-04-02
CN111372921B (zh) 2023-12-01
IL273242B1 (en) 2023-04-01
US20220340534A1 (en) 2022-10-27
EP3681874B1 (en) 2022-04-06
KR20200053560A (ko) 2020-05-18
US11912669B2 (en) 2024-02-27
EP3681874A1 (en) 2020-07-22
IL273242B2 (en) 2023-08-01
US20240246919A1 (en) 2024-07-25
WO2019055528A1 (en) 2019-03-21
US12404251B2 (en) 2025-09-02
KR102644045B1 (ko) 2024-03-05
CN111372921A (zh) 2020-07-03
AU2018331371C1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
AU2019216351B2 (en) Combination therapy for the treatment of mastocytosis
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
CN111789956B (zh) 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒
JP6666494B2 (ja) がんの処置のための医薬の組合せ
KR20240021884A (ko) 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도
JP2010539104A (ja) ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療
US12404251B2 (en) Small molecule compound
DE102010035744A1 (de) Imidazolonylchinoline
WO2014140072A1 (en) Etoposide and prodrugs thereof for use in targeting cancer stem cells
US20240355686A1 (en) Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers
KR102011105B1 (ko) 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물
KR101855382B1 (ko) 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물
TWI403320B (zh) 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US12454514B2 (en) Quinazolinone compounds
BR112012033344B1 (pt) Composto de quinazolina, composição farmacêutica, método in vitro para inibir a superexpressão e/ou hiperatividade do receptor do fator de crescimento epidérmico e uso do composto
US10512631B2 (en) Chalcone compounds
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
WO2007062030A2 (en) Quinuclidinone derivatives as anticancer agents

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221025

R150 Certificate of patent or registration of utility model

Ref document number: 7170341

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250